See more : AlphaTime Acquisition Corp Right (ATMCR) Income Statement Analysis – Financial Results
Complete financial analysis of Millendo Therapeutics, Inc. (MLND) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Millendo Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cadiz Inc. (CDZIP) Income Statement Analysis – Financial Results
- Anupam Rasayan India Limited (ANURAS.BO) Income Statement Analysis – Financial Results
- Lumax Auto Technologies Limited (LUMAXTECH.BO) Income Statement Analysis – Financial Results
- Beijing Huayuanyitong Thermal Technology Co., Ltd. (002893.SZ) Income Statement Analysis – Financial Results
- PICC Property and Casualty Company Limited (PPCCF) Income Statement Analysis – Financial Results
Millendo Therapeutics, Inc. (MLND)
About Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 295.00K | 653.00K | 277.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 790.00K | 5.40M | 2.25M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -495.00K | -4.75M | -1.97M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -167.80% | -727.11% | -711.91% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.37M | 27.84M | 14.43M | 18.34M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M |
| General & Administrative | 15.60M | 17.56M | 12.45M | 0.00 | 0.00 | 0.00 | 0.00 | 13.33M | 7.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.60M | 17.56M | 12.45M | 0.00 | 0.00 | 0.00 | 0.00 | 13.33M | 7.21M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 27.74M | 49.22M | 51.59M | 26.15M | 0.00 | 0.00 |
| Operating Expenses | 35.97M | 45.40M | 26.87M | 46.08M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M |
| Cost & Expenses | 35.97M | 45.40M | 26.87M | 46.87M | 76.27M | 72.28M | 47.93M | 29.13M | 13.53M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | -1.04M | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.10M | 1.05M | 32.00K | 1.65M | 2.24M | 1.29M | 450.00K | 231.00K | 93.00K |
| EBITDA | -35.30M | -44.55M | -27.03M | -49.26M | -79.82M | -71.86M | -49.07M | -28.81M | -13.42M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -16,697.63% | -12,223.74% | -25,941.52% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.97M | -45.40M | -26.87M | -46.58M | -75.61M | -72.00M | -47.93M | -29.13M | -13.53M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -15,788.47% | -11,579.17% | -25,992.42% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -434.00K | 831.00K | -303.00K | -4.33M | -6.45M | -1.15M | -1.59M | 90.00K | 19.00K |
| Income Before Tax | -36.41M | -44.57M | -27.18M | -50.91M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -17,256.95% | -12,566.46% | -26,405.78% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -434.00K | -207.00K | -169.00K | 67.00K | 201.00K | 75.00K | -1.59M | 90.00K | 19.00K |
| Net Income | -36.41M | -44.57M | -27.19M | -50.98M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -17,279.66% | -12,597.24% | -26,432.85% | 0.00% | 0.00% | 0.00% |
| EPS | -28.95 | -48.77 | -263.65 | -321.49 | -575.72 | -608.24 | -491.98 | -404.39 | -523.20 |
| EPS Diluted | -28.95 | -48.77 | -263.65 | -321.49 | -575.72 | -608.24 | -491.98 | -404.39 | -523.20 |
| Weighted Avg Shares Out | 1.26M | 913.79K | 103.14K | 158.56K | 142.88K | 120.38K | 100.65K | 71.82K | 25.82K |
| Weighted Avg Shares Out (Dil) | 1.26M | 913.79K | 103.14K | 158.56K | 142.88K | 120.38K | 100.65K | 71.82K | 25.82K |
Millendo Therapeutics Inc (NASDAQ:MLND) Sees Significant Increase in Short Interest
Millendo Therapeutics Inc (NASDAQ:MLND) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 755,100 shares, a growth of 34.6% from the June 15th total of 561,100 shares. Based...
Millendo Therapeutics (NASDAQ:MLND) Trading Down 3.8%
Shares of Millendo Therapeutics Inc (NASDAQ:MLND) dropped 3.8% during trading on Wednesday . The company traded as low as $1.96 and last traded at $1.92, approximately 55,363 shares were traded during trading. A decline of 98% from the average daily...
Millendo Therapeutics Provides Corporate and Pipeline Update
Millendo Therapeutics Provides Corporate and Pipeline Update.
Millendo Therapeutics (NASDAQ:MLND) Shares Gap Down to $2.71
Millendo Therapeutics Inc (NASDAQ:MLND) gapped down before the market opened on Friday . The stock had previously closed at $2.61, but opened at $2.71. Millendo Therapeutics shares last traded at $2.78, with a volume of 46,125 shares. Several equities analysts...
Millendo Therapeutics Reports First Quarter 2020 Operating and Financial Results
Millendo Therapeutics Reports First Quarter 2020 Operating and Financial Results
Leonardo books first-quarter loss, braces for higher virus impact in second quarter
Italian defence group Leonardo warned on Thursday that the coronavirus outbreak would have a bigger impact in the second quarter, after reporting a net loss in the first three months.
GBP/CHF Continuation
Forex Analysis by Scott Barkley covering: GBP/CHF. Read Scott Barkley's latest article on Investing.com
USD/CAD Continuation
Forex Analysis by Scott Barkley covering: USD/CAD. Read Scott Barkley's latest article on Investing.com
GBP/USD Continuation
Forex Analysis by Scott Barkley covering: . Read Scott Barkley's latest article on Investing.com
What Are The Best Penny Stocks To Watch This Week? 3 For Your List
Are These On Your List Of Penny Stocks To Watch In May 2020? May 03, 2020 (Penny Stocks via COMTEX) -- Regardless of which names are on your list of penny...
Source: https://incomestatements.info
Category: Stock Reports